Search Results

Containing any of the words

Only of the type

A phase 3, multi-center, open-label, randomized study of oral ABL001 versus bosutinib in patients with Chronic Myelogenous Leukemia in chronic phase (CML-CP), previously treated with 2 or more tyrosine kinase inhibitors Drug Clinical Trial

A study of the factors predicting radiation exposure to contacts of Saudi patients treated with radioactive iodine (I 131): A preliminary study for patients’ criteria selection for possible high dose I131 therapy on out-patient basis in the future Drug Clinical Trial

A phase 3, multi-center, open-label, randomized study of oral ABL001 versus bosutinib in patients with Chronic Myelogenous Leukemia in chronic phase (CML-CP), previously treated with 2 or more tyrosine kinase inhibitors Drug Clinical Trial

Phase I/II Study of a Lentigen® CD19 Chimeric Antigen Receptor (CAR) T Cells in Adult patients with relapsed/refractory CD19 Positive Non-Hodgkin’s Lymphoma (NHL) using a Closed Transduction System Drug Clinical Trial

(SG-2111-364-H) Security Advisory regarding Philips MRI 1.5T and 3T release 5 Medical Report

A Phase 2/3, Open-Label, Randomized, Controlled, Multicenter Study of KYV-101, an Autologous Fully Human Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, Versus Ongoing Standard-Of-Care Immunosuppressive Therapy in Patients with Generalized Myasthenia Gravis (KYSA-6). Drug Clinical Trial

Evaluation of Purified Poloxamer 188 in Vaso-Occlusive Crisis of Sickle Cell Disease (EPIC): A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial of MST-188 (Purified Poloxamer 188) Injection in Subjects With Sickle Cell Disease Experiencing Vaso Occlusive Crisis Drug Clinical Trial

Evaluation of Purified Poloxamer 188 in Vaso-Occlusive Crisis of Sickle Cell Disease (EPIC): A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial of MST-188 (Purified Poloxamer 188) Injection in Subjects With Sickle Cell Disease Experiencing Vaso Occlusive Crisis Drug Clinical Trial

A Phase 3, Prospective, Multicenter, Double-blind, Double-dummy, Randomized, Active controlled, Parallel-group, Group-sequential, Adaptive, Event-driven Study to Compare Efficacy, Safety, and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension, Followed by an Open-label Treatment Period With Macitentan 75 mg. (UNISUS) Drug Clinical Trial

SAFETY AND THERAPEUTIC MEASURES OF TDCS IN PATIENTS WITH REFRACTORY EPILEPSY Clinical Trial